D.A. Davidson & CO. Increases Stock Position in Zoetis Inc. (NYSE:ZTS)

D.A. Davidson & CO. grew its position in shares of Zoetis Inc. (NYSE:ZTS) by 4.3% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 25,979 shares of the company’s stock after buying an additional 1,062 shares during the quarter. D.A. Davidson & CO.’s holdings in Zoetis were worth $5,076,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Mizuho Securities USA LLC raised its stake in Zoetis by 13,726.9% during the 3rd quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock valued at $950,524,000 after acquiring an additional 4,829,815 shares during the last quarter. Sarasin & Partners LLP increased its holdings in shares of Zoetis by 546.3% in the second quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company’s stock valued at $390,682,000 after purchasing an additional 1,904,899 shares during the period. International Assets Investment Management LLC lifted its holdings in shares of Zoetis by 41,235.7% during the third quarter. International Assets Investment Management LLC now owns 939,974 shares of the company’s stock worth $183,652,000 after purchasing an additional 937,700 shares during the period. Marshall Wace LLP lifted its holdings in shares of Zoetis by 7,608.6% during the second quarter. Marshall Wace LLP now owns 835,684 shares of the company’s stock worth $144,874,000 after purchasing an additional 824,843 shares during the period. Finally, Swedbank AB grew its position in Zoetis by 56.2% in the 2nd quarter. Swedbank AB now owns 1,946,277 shares of the company’s stock valued at $337,407,000 after buying an additional 700,398 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

NYSE ZTS opened at $176.74 on Thursday. The business has a 50 day moving average price of $184.51 and a 200 day moving average price of $180.81. The company has a market capitalization of $79.74 billion, a P/E ratio of 33.22, a PEG ratio of 2.70 and a beta of 0.90. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. The business had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same quarter last year, the business posted $1.36 earnings per share. Sell-side analysts expect that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be paid a dividend of $0.432 per share. The ex-dividend date is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.98%. Zoetis’s dividend payout ratio (DPR) is 32.52%.

Analyst Ratings Changes

ZTS has been the subject of several recent analyst reports. Argus upgraded shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. BTIG Research lifted their price objective on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. Stifel Nicolaus increased their target price on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, September 18th. JPMorgan Chase & Co. lifted their price target on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Finally, Piper Sandler increased their price objective on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Zoetis presently has an average rating of “Buy” and an average price target of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.